Lambertini M

No ORCID on file · 4 papers in corpus · active 2013-2024
2024
Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review.
BMJ oncology ·doi:10.1136/bmjonc-2024-000330

Transgender and gender-diverse (TGD) individuals face an elevated risk of cancer in comparison with the general population. This increased risk is primarily attributed to an imbalanced exposure to modifiable risk factors and a limited adher…

2022
Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
Human reproduction update ·doi:10.1093/humupd/dmac004

BackgroundFemale patients undergoing anticancer treatment are at elevated risk of adverse ovarian outcomes including infertility and premature ovarian insufficiency (POI), which is associated with short- and long-term health risks. Anti-Mül…

2020
ESHRE guideline: female fertility preservation.
Human reproduction open ·doi:10.1093/hropen/hoaa052

Study questionWhat is the recommended management for women and transgender men with regards to fertility preservation (FP), based on the best available evidence in the literature?Summary answerThe ESHRE Guideline on Female Fertility Preserv…

2013
Fertility counseling of young breast cancer patients.
Journal of thoracic disease ·doi:10.3978/j.issn.2072-1439.2013.05.22

Approximately 6% of women with breast cancer are diagnosed before the age of 40. Young age is an independent predictor of adverse outcome and most young breast cancer patients receive systemic treatment with chemotherapy, hormonal therapy o…